Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2022-12-21 00:00:00 ET · period of report 2022-12-19 · accession 0001127602-22-028082 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-21 | 2022-12-19 | BCRX | Thackray Helen M. | Chief R, D Off | A - Grant | $0.00 | +81.0K | 214.3K | +61% | $0 |
| D | 2022-12-21 | 2022-12-19 | BCRX | Thackray Helen M. | Chief R, D Off | A - Grant | $0.00 | +238.0K | 238.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-19 | A | A | 81,000 | $0.00 | 214,275 | D | — | — | (F1) Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 2 | Derivative | Emp. Stock Option (Right to Buy) | 2022-12-19 | A | A | 238,000 | $0.00 | 238,000 | D | $10.63 · 2023-12-19 to 2032-12-19 | 238,000 Common Stock | (F2) Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |